Another phase II trial (NCT01627067) evaluated the efficacy and safety of combining metformin with the mTOR inhibitor everolimus and the aromatase inhibitor exemestane in overweight and obese postmenopausal woman with metastatic, ER-positive/HER2-negative breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.